ES2164218T3 - Derivados de camptotecina. - Google Patents

Derivados de camptotecina.

Info

Publication number
ES2164218T3
ES2164218T3 ES96309470T ES96309470T ES2164218T3 ES 2164218 T3 ES2164218 T3 ES 2164218T3 ES 96309470 T ES96309470 T ES 96309470T ES 96309470 T ES96309470 T ES 96309470T ES 2164218 T3 ES2164218 T3 ES 2164218T3
Authority
ES
Spain
Prior art keywords
alkylene
groups
camptothecin
alkm
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96309470T
Other languages
English (en)
Inventor
Kenji Tsujihara
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2164218T3 publication Critical patent/ES2164218T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

UN DERIVADO DE CAMPTOTECINA QUE COMPRENDE UN COMPUESTO DE LA FORMULA [I]: EN DONDE R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUP,4} Y R{SUP,5} SON (A) UNA COMBINACION DE DOS GRUPOS ADYACENTES PARA FORMAR ALQUILENO, O AMBOS SON H, Y UNO DE LOS TRES GRUPOS RESTANTES ES X{SUB,N}-ALQ{SUB,M}-R{SUP,6}, Y LOS OTROS DOS SON H, ALQUILO O HALOGENO, O (B) UNA COMBINACION DE DOS GRUPOS ADYACENTES PARA FORMAR ALQUILENO, Y UNO DE LOS ATOMOS DE CARBONO DE DICHO GRUPO ALQUILENO ESTA SUSTITUIDO POR -X{SUB,N}-ALQ{SUB,M}-R{SUP,6}, Y LOS TRES GRUPOS RESTANTES SON H, ALQUILO O UN HALOGENO, Y UNO O DOS -CH{SUB,2}- DEL ALQUILENO EN (A) O (B) PUEDE SER OPCIONALMENTE SUSTITUIDO POR -O-, -S- O -NH-, X ES -O O -NH-, ALQ ES ALQUILENO, R{SUP,6} ES -NH{SUB,2}, O -OH, M Y N SON 0 O 1, O M ES 1 Y N ES 0, EL MENCIONADO COMPUESTO DE CAMPTOTECINA ES UNIDO A UN POLISACARIDO QUE TIENE GRUPOS CARBOXILICOS MEDIANTE UN AMINOACIDO O UN PEPTIDO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. DICHOS DERIVADOS DE CAMPTOTECINA MUESTRAN ACTIVIDADES ANTITUMORALES MEJORADAS PERO POCOS EFECTOS LATERALES Y SON UTILES COMO UN MEDICAMENTO.
ES96309470T 1995-12-28 1996-12-23 Derivados de camptotecina. Expired - Lifetime ES2164218T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34357595 1995-12-28
JP20010596 1996-07-30

Publications (1)

Publication Number Publication Date
ES2164218T3 true ES2164218T3 (es) 2002-02-16

Family

ID=26511972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96309470T Expired - Lifetime ES2164218T3 (es) 1995-12-28 1996-12-23 Derivados de camptotecina.

Country Status (15)

Country Link
US (3) US5892043A (es)
EP (1) EP0781781B1 (es)
KR (1) KR100352545B1 (es)
CN (2) CN1073113C (es)
AT (1) ATE206720T1 (es)
CA (1) CA2192725C (es)
DE (1) DE69615808T2 (es)
DK (1) DK0781781T3 (es)
ES (1) ES2164218T3 (es)
GR (1) GR3037076T3 (es)
ID (1) ID25979A (es)
MX (1) MX9700222A (es)
PT (1) PT781781E (es)
SG (2) SG49994A1 (es)
TW (1) TW473478B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888988A (en) * 1995-05-08 1999-03-30 Chitogenics, Inc. Covalently linked N,O-carboxymethylchitosan and uses thereof
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE19640207A1 (de) * 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
JP2001504453A (ja) * 1996-09-30 2001-04-03 バイエル・アクチエンゲゼルシヤフト 改変カンプトテシン誘導体からの複合糖質（２０―ｏ―結合）
SG88737A1 (en) * 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
CN1250293C (zh) * 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
CA2352338A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
SG147286A1 (en) * 1999-10-12 2008-11-28 Cell Therapeutics Inc Manufacture of polyglumate-therapeutic agent conjugates
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
CN100393724C (zh) * 2002-07-12 2008-06-11 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
EP1796644B1 (en) * 2004-09-07 2011-04-13 Biocompatibles UK Limited Drug delivery from embolic agents
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
HUE039000T2 (hu) 2012-10-11 2018-12-28 Daiichi Sankyo Co Ltd Antitest-gyógyszer konjugát
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CA2933666C (en) 2013-12-25 2021-08-03 Sapporo Medical University Anti-trop2 antibody-drug conjugate
DK3466976T3 (da) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
KR102624244B1 (ko) 2014-04-10 2024-01-11 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018135501A1 (ja) 2017-01-17 2018-07-26 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体－薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
KR102630307B1 (ko) 2017-08-31 2024-01-29 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
CA3100608A1 (en) 2018-05-18 2019-11-21 Daiichi Sankyo Co., Ltd. Anti-muc1 antibody-drug conjugate
KR20230004453A (ko) 2020-02-25 2023-01-06 메디보스턴 리미티드 캄프토테신 유도체 및 이의 접합체
KR20230142710A (ko) * 2021-02-05 2023-10-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
CN113952465A (zh) * 2021-10-20 2022-01-21 中国药科大学 一种喜树碱前药及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220601B1 (en) 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
JP2540357B2 (ja) 1987-06-24 1996-10-02 第一製薬株式会社 六環性化合物
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ES2086643T3 (es) 1991-10-29 1996-07-01 Glaxo Wellcome Inc Derivados de camptotecina solubles en agua.
JPH06228141A (ja) 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1994019376A1 (en) 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives

Also Published As

Publication number Publication date
TW473478B (en) 2002-01-21
GR3037076T3 (en) 2002-01-31
EP0781781A3 (en) 1998-04-01
MX9700222A (es) 1998-04-30
PT781781E (pt) 2002-03-28
EP0781781A2 (en) 1997-07-02
ATE206720T1 (de) 2001-10-15
KR970042553A (ko) 1997-07-24
CN1073113C (zh) 2001-10-17
US6617456B1 (en) 2003-09-09
DE69615808T2 (de) 2002-05-02
EP0781781B1 (en) 2001-10-10
CN1142935C (zh) 2004-03-24
CA2192725A1 (en) 1997-06-29
KR100352545B1 (ko) 2003-01-24
CA2192725C (en) 2004-04-20
US5892043A (en) 1999-04-06
US6512118B1 (en) 2003-01-28
SG49994A1 (en) 1998-06-15
DE69615808D1 (de) 2001-11-15
CN1158334A (zh) 1997-09-03
ID25979A (id) 1997-06-26
CN1300733A (zh) 2001-06-27
DK0781781T3 (da) 2001-11-26
SG76585A1 (en) 2000-11-21

Similar Documents

Publication Publication Date Title
ES2164218T3 (es) Derivados de camptotecina.
DK0757049T3 (da) Camptothecinderivater
BG100635A (en) Substituted n-/indol-2-carbonyl/- - alanineamides and their derivatives as antidiabestic preparations
TR200100438T2 (tr) Hepatit C inhibitörü peptitler
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
IL129238A0 (en) N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds
PT753301E (pt) Combinacao de um benzimidazole tendo actividade antagonista da angiotensina ii com um diuretico
ES2120728T3 (es) Inhibidores de la agregacion de plaquetas.
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
ATE142641T1 (de) Neue peptid-verbindungen und verfahren zur herstellung davon
KR910002899A (ko) 혈조절 펩타이드
RS91204A (en) Lyophilized and liquid preparation comprising a polysaccharide derivative of camptothecin
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
EP0376041A3 (en) C63-amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
MX9603149A (es) Derivados de camptotecina.
ATE243219T1 (de) 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
ATE255121T1 (de) Antitumor-indolopyrolocarbazolderivat
DK0835265T3 (da) Blodpladeaggregeringsinhibitorer indeholdende C-terminale aminosyrerester med aminerge sidekæder

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 781781

Country of ref document: ES